14-hydroxy-4,14-retro-retinol signaling pathway (14-HRR signaling)

14-hydroxy-4,14-retro-retinol (14-HRR) is a bioactive metabolite of retinol (Vitamin A) that serves as a critical intracellular messenger in the immune system, specifically within lymphocytes (Science, 1991, 254:1654-6). Unlike the well-known retinoic acid pathway which regulates gene transcription via nuclear receptors (RAR/RXR), 14-HRR functions through a distinct, retro-retinoid-dependent signaling machinery to promote the growth and survival of B cells and the activation of T cells (Biochemistry, 1994, 33:623-8). This pathway involves the direct binding and activation of Protein Kinase C alpha (PKCα) and c-Raf by 14-HRR, which triggers downstream signaling cascades necessary for lymphocyte proliferation (J. Exp. Med., 2000, 192:835-45; J. Biol. Chem., 2005, 280:6872-9). This mechanism is essential for maintaining a robust immune response, as Vitamin A deficiency leads to impaired lymphocyte function and increased susceptibility to infections. Anhydroretinol (AR), another naturally occurring retro-retinoid, acts as a competitive antagonist to 14-HRR, providing a regulatory balance for lymphocyte physiology (J. Exp. Med., 1993, 178:675-80). The 14-HRR signaling machinery represents a potential therapeutic target for modulating immune responses in conditions such as autoimmune diseases or certain lymphoid malignancies.

Other names

14-hydroxy-4,14-retro-retinol-dependent signaling machinery14-HRR pathwayRetro-retinoid signaling pathway14-hydroxy-retro-retinol

14-hydroxy-4,14-retro-retinol (14-HRR) acts as an intracellular second messenger that binds to and activates Protein Kinase C alpha (PKCα) and c-Raf in lymphocytes. This activation is essential for B-cell growth and T-cell activation, providing a signaling mechanism distinct from the classical retinoic acid receptor (RAR) pathway. Anhydroretinol (AR) acts as a competitive antagonist, inhibiting 14-HRR-dependent growth and potentially inducing apoptosis.